These results indicate that the PDCD1 rs11568821 G>A polymorphism may contribute as a potential susceptibility and prognosis marker for breast cancer, especially for ER+/PR+ subtypes, considering the importance of PD-1 inhibitor effect over anti-tumor response.

P=N/A, N=659, Not yet recruiting, Shady Grove Fertility Reproductive Science Center

P=N/A, N=40, Not yet recruiting, University Hospital, Montpellier | Initiation date: Sep 2025 --> Jan 2026

Fluzoparib, the domestically developed PARPi in China, has demonstrated significant efficacy in BRCA-mutated ovarian cancer. In the field of supportive care, megestrol acetate (MA) is recommended as the first-line preferred therapeutic agent for cancer-related anorexia by major guidelines, though its role in first-line ovarian cancer therapy remains unexplored, and evidence for its combination with PARPi is lacking...Imaging assessments revealed significant tumor reduction without disease progression or grade ≥3 adverse events observed throughout follow-up. This case highlights the potential of combining PARPi and hormone therapy as a 'chemotherapy-free' precision treatment model for elderly and HRD-positive ovarian cancer patients, offering a promising strategy to balance efficacy and tolerability in a population traditionally underserved by conventional regimens.

P=N/A, N=320, Recruiting, University Hospital, Montpellier | Not yet recruiting --> Recruiting

P2, N=0, Withdrawn, Saskatchewan Health Authority - Regina Area | Terminated --> Withdrawn

9 core genes (CCNB1, CCNB2, MAD2L1, BUB1, TTK, CDC20, AURKA, RRM2, GTSE1) were obtained through the KEGG pathway enrichment, which mainly enriched in 4 pathways, namely, Cell cycle, Oocyte meiosis, p53 signaling pathway, and Progesterone-mediated oocyte maturation, respectively. Nine critical dependable DEGs were identified in limited-stage NSCLC using integrated bioinformatical approaches, and these core genes show great potential as prospective biomarkers and therapeutic targets in the progression of limited-stage NSCLC. non-small cell lung cancer, biomarkers, therapeutic targets, p53 signaling pathway, bioinformatics analysis.

P3, N=3055, Terminated, Organon and Co | N=2007 --> 3055

P=N/A, N=150, Not yet recruiting, Ege University

P4, N=495, Recruiting, Changchun GeneScience Pharmaceutical Co., Ltd.

Furthermore, treatment with the antioxidant resveratrol (RSV) and its nanoformulation (RSV-NPs) markedly inhibited tumor growth in mice with lipid metabolic disorders, highlighting their potential to counteract progesterone resistance by disrupting this OLR1/FOXM1/FGF19 axis. This work highlights the therapeutic potential of targeting the tumor-stroma metabolic axis to increase progesterone sensitivity and improve outcomes in EC patients with fertility-preserving demands.

In both 2D monolayer and 3D culture, tAEC21 cells responded to 17β-estradiol (E2) but did not respond to progesterone (P4), consistent with the expression of estrogen (ESR1) and progesterone (PGR) receptors. This new epithelial-like, adenomyosis-derived cell line, tAEC21, will be an impactful, biologically plausible research resource.